BERGEN, Norway--(BUSINESS WIRE)--BerGenBio AS, an emerging oncology biopharma, is developing a first in class inhibitor of Axl kinase, BGB324. Promising preclinical data on the importance of Axl kinase in Acute Myeloid Leukemia (AML) will be presented at the 53rd American Society of Hematology Annual Meeting and Exposition, in San Diego. The research, completed by Sonja Loges, M.D., Ph.D. from University of Hamburg, suggests that Axl is a useful prognostic indictor for AML and that BerGenBio`s inhibitor, BGB324, is a highly effective therapeutic candidate.
